TrialAnnals of the rheumatic diseases2019

Phase IIa, placebo-controlled, randomised study of lutikizumab, an anti-interleukin-1α and anti-interleukin-1β dual variable domain immunoglobulin, in patients with erosive hand osteoarthritis.

Margreet Kloppenburg et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.